Regeneron Pharmaceuticals Inc vs Silicon Motion Technology Corporation American Depositary Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $784.4 (market cap $77.54B), while Silicon Motion Technology Corporation American Depositary Shares trades at $220 (market cap $8.36B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 9.3× Silicon Motion Technology Corporation American Depositary Shares's market cap, and Silicon Motion Technology Corporation American Depositary Shares pays the higher dividend (0.81%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Silicon Motion Technology Corporation American Depositary Shares for 0 Days on average.
| REGN | SIMO | |
|---|---|---|
Market Cap | $77.54B | $8.36B |
Volume | 629,519 | 663,682 |
Sector | Health | Technology |
52-Week High | $852.03 | $336.90 |
52-Week Low | $569.17 | $80.16 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $72.25B | $8.35B |
Dividend Yield | 0.5% | 0.81% |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $778.36, up 2.04% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant expansion of its immunology alliance with Sanofi, valued up to $8 billion, which could drive future growth. Valuation ratios appear reasonable, with a P/E of 18.64 and robust profitability margins.
The outlook for REGN is positive, supported by strong earnings momentum, a lucrative partnership expansion, and a unanimous analyst buy consensus. Key risks include competitive pressures in the biopharma space and reliance on key drug performance. The stock presents a compelling opportunity for growth investors, with a consensus price target of $849.84 suggesting upside potential.
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →